Status:
COMPLETED
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Growth Hormone Disorder
Adult Growth Hormone Deficiency
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This trial is conducted in Japan. To investigate the long-term efficacy as assessed by change in fat mass and safety after 48 weeks of treatment of Growth Hormone in adults with Growth Hormone Deficie...
Eligibility Criteria
Inclusion
- Subjects who completed GHLiquid-1518.
- If the subject has a history of treatment for a tumor of pituitary or peripheral site, two years or more have to be passed since completion of surgery, radiotherapy or other treatment, and recurrence of the underlying disease to be excluded.
- Appropriate replacement therapy has been administered for more than 24 weeks for the treatment of other pituitary hormone deficiencies.
Exclusion
- Subject with a history of acromegaly.
- Subject with diabetes mellitus.
- Subject suffering from malignancy.
- Several medical conditions
Key Trial Info
Start Date :
December 6 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 28 2005
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT00184743
Start Date
December 6 2003
End Date
December 28 2005
Last Update
February 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Tokyo, Japan, 1000005